Expanding access to maggot containment dressings through redesign and innovation
- PMID: 39800339
- PMCID: PMC11725371
- DOI: 10.1111/iwj.70100
Expanding access to maggot containment dressings through redesign and innovation
Abstract
There are two major styles of maggot debridement dressings: (1) confinement dressings that form a cage around the wound, and (2) containment dressings that completely surround the maggots within a sealed porous bag. For producers and clinicians wanting to prepare containment dressings using readily available polyester bags, it is currently difficult to seal these bags without expensive high-temperature plastic welders. This study aimed to identify simple and affordable methods for sealing maggots within polyester net bags. Heat sealing was the most effective and simplest method to seal the polyester net bags, but the high melting point of polyester required industrial grade heat sealers. An inner lining of polyethylene or polypropylene film at the open side of the bag allowed for complete sealing using low-cost hand-actuated impulse heat sealers. This design even facilitated the addition of plastic zipper-locks, allowing secure closure of the bag without electricity or special equipment. Other sealing methods were identified, but most were time-consuming, required practice or not consistently successful. The maggot containment bag designs and closure methods described herein should prove useful to clinicians without access to contained maggots and to maggot producers without the resources to seal polyester containment bags. Clinical trials are expected to follow.
Keywords: debridement; dressing; larva; maggot; wound.
© 2025 The Author(s). International Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons Ltd.
Conflict of interest statement
Dr. Sherman discloses that, when this research was initiated, he was co‐founder and Laboratory Director of Monarch Labs, a company that produced and distributed medicinal maggots in the United States. Dr. Sherman subsequently retired from, and divested from, Monarch Labs; he is no longer the owner, shareholder or employee of any wound care company. Dr. Sherman is the Director of the not‐for‐profit BioTherapeutics, Education and Research (BTER) Foundation, whose mission is to advance health care through education and research in biotherapy. To minimize conflicts of interest, he accepts no remuneration for the administrative, research, teaching, patient care or other services that he performs for this charity and its clients. To further minimize conflicts of interest, Dr. Sherman earns his living by working in an unrelated field: as an HIV/AIDS physician for the Health Care Agency of Orange County, California. Dr. Stadler is the director of MedMagLabs, a Similitude Pty Ltd. business aiming to supply medicinal maggots in Australia and elsewhere, particularly in low‐and middle‐income countries and compromised healthcare settings. The technology described in this publication is likely to facilitate low‐cost delivery of maggot therapy services in such markets.
Figures
References
-
- Sherman RA, Wyle F, Vulpe M. Maggot therapy for treating pressure ulcers in spinal cord injury patients. J Spinal Cord Med. 1995;18(2):71‐74. - PubMed
-
- Wayman J, Nirojogi V, Walker A, Sowinski A, Walker MA. The cost effectiveness of larval therapy in venous ulcers. J Tissue Viability. 2000;10(3):91‐94. - PubMed
-
- Sherman RA. Maggot versus conservative debridement therapy for the treatment of pressure ulcers. Wound Repair Regen. 2002;10(4):208‐214. - PubMed
-
- Sherman RA. Maggot therapy for treating diabetic foot ulcers unresponsive to conventional therapy. Diabetes Care. 2003;26(2):446‐451. - PubMed
-
- Armstrong DG, Salas P, Short B, et al. Maggot therapy in “lower‐extremity hospice” wound care: fewer amputations and more antibiotic‐free days. J Am Podiatr Med Assoc. 2005;95(3):254‐257. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
